DURHAM, N.C., June 13, 2016 — Premier Research is expanding its international organization of experts in rare disease amid continued growth in the field — especially in rare oncology, which has surpassed one-third of the company’s rare disease work. “Development of novel compounds for treatment of unmet medical needs historically has been overlooked by big pharma,...
PHILADELPHIA, FEBRUARY 24, 2016 — There’s a lot to consider when investigating a novel and targeted oncology compound, and decisions you make early on can have profound and lasting implications. At a webinar on Wednesday, February 24, Premier Research will show how making sound decisions from the outset can improve your odds of long-term success....
PHILADELPHIA, December 17, 2015 — Premier Research announces the appointment of Paul Hallenbeck as Executive Director for Oncology. Dr. Hallenbeck has more than 20 years of experience in the biotech industry and expertise in all phases of oncology drug discovery, development, and commercialization, including work in complex, targeted biologics. Dr. Hallenbeck most recently served as...